SRC and non-small cell lung carcinoma: These combination therapies are mainly based on the result that Src activation contributes to the resistance to EGFR-TKIs in EGFR-mutant NSCLC, and the combination of an EGFR-TKI and a Src inhibitor is synergistic in these tumors.